Aurobindo Pharma receives US FDA nod for hypertension drug esmolol hydrochloride

The US Food & Drug Administration (US FDA) has granted Aurobindo Pharma Limited final approval for manufacturing and marketing of esmolol hydrochloride injection in strength of 100 mg/10mL.
 
Esmolol hydrochloride injection is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Brevibloc injection of Baxter Healthcare Corporation. Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period.